The H5N1 avian influenza virus is mutating to evade immune defenses in mammals following prior infection or vaccination.

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

New imaging reveals a built-in safeguard that allows B cell populations to rapidly expand in germinal centers without ...

New computational modeling of avian influenza variants’ immunoprotein interactions – developed by a research team at the University of North Carolina at Charlotte – reveals the H5N1 influenza virus is ...

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...

The H5N1 influenza virus poses a significant threat to public health due to its potential to shift from an epidemic to a pandemic. Since its emergence in the 1990s, H5N1 has demonstrated a concerning ...

Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of ...

Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...